Cyclacel Pharmaceuticals (CYCC) Stock Forecast & Price Target

$1.73

+0.05 (+2.98%)

(As of 07/26/2024 ET)

Cyclacel Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 2 Analyst Ratings

Based on 2 Wall Street analysts who have issued ratings for Cyclacel Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 2 analysts, 1 has given a hold rating, and 1 has given a buy rating for CYCC.

Consensus Price Target

$11.00
535.84% Upside

High Forecast	$11.00
Average Forecast	$11.00
Low Forecast	$11.00

According to the 2 analysts' twelve-month price targets for Cyclacel Pharmaceuticals, the average price target is $11.00. The highest price target for CYCC is $11.00, while the lowest price target for CYCC is $11.00. The average price target represents a forecasted upside of 535.84% from the current price of $1.73.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$11.00	$11.00	$21.00	$120.00
Forecasted Upside	535.84% Upside	384.58% Upside	481.07% Upside	997.69% Upside

Get Cyclacel Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

Obama wins Presidential debate

When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.”

Please, watch this now before it’s too late.

CYCC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CYCC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cyclacel Pharmaceuticals Stock vs. The Competition

Type	Cyclacel Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	532.73% Upside	2,840.05% Upside	9.13% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/3/2024	Roth Mkm 1 of 5 stars		Lower Target	Buy ➝ Buy	$21.00 ➝ $11.00	+384.58%
12/19/2023	Brookline Capital Management 5 of 5 stars	K. Dolliver Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/7/2023	Oppenheimer 3 of 5 stars		Lower Target	Outperform	$150.00 ➝ $120.00	+997.69%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:15 AM ET.

CYCC Forecast - Frequently Asked Questions

What is Cyclacel Pharmaceuticals' forecast for 2024?: According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Cyclacel Pharmaceuticals is $11.00, with a high forecast of $11.00 and a low forecast of $11.00.
Should I buy or sell Cyclacel Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There is currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYCC shares.
Does Cyclacel Pharmaceuticals's stock price have much upside?: According to analysts, Cyclacel Pharmaceuticals's stock has a predicted upside of 384.58% based on their 12-month stock forecasts.
What analysts cover Cyclacel Pharmaceuticals?: Cyclacel Pharmaceuticals has been rated by research analysts at Roth Mkm in the past 90 days.
Do Wall Street analysts like Cyclacel Pharmaceuticals more than its competitors?: Analysts like Cyclacel Pharmaceuticals less than other "medical" companies. The consensus rating score for Cyclacel Pharmaceuticals is 2.50 while the average consensus rating score for "medical" companies is 2.72. Learn more on how CYCC compares to other companies.